Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) CFO Matt Abernethy sold 14,100 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total transaction of $2,120,358.00. Following the transaction, the chief financial officer now owns 31,528 shares in the company, valued at approximately $4,741,180.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Neurocrine Biosciences Stock Up 0.7 %
Shares of NBIX stock traded up $1.08 during trading hours on Thursday, hitting $147.77. 720,170 shares of the company’s stock were exchanged, compared to its average volume of 819,548. The firm has a market cap of $14.87 billion, a P/E ratio of 40.55 and a beta of 0.37. The firm has a 50 day moving average of $141.47 and a two-hundred day moving average of $138.88. Neurocrine Biosciences, Inc. has a fifty-two week low of $103.63 and a fifty-two week high of $157.98.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.15 by ($0.52). The business had revenue of $590.20 million for the quarter, compared to analyst estimates of $545.98 million. Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The company’s quarterly revenue was up 30.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.95 earnings per share. On average, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of brokerages recently commented on NBIX. Robert W. Baird upped their target price on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Wells Fargo & Company upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $140.00 to $170.00 in a research report on Wednesday, April 24th. Barclays upped their target price on Neurocrine Biosciences from $169.00 to $180.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Morgan Stanley upped their target price on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, July 12th. Finally, JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Six equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $158.68.
Get Our Latest Analysis on NBIX
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Read More
- Five stocks we like better than Neurocrine Biosciences
- 5 discounted opportunities for dividend growth investors
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Jeff Brown’s Exegesis AI Stock Picks
- How to Use the MarketBeat Stock Screener
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.